Skip to main content
Steven Nathan on Muck Rack

Steven Nathan

Scranton
As seen in: PLOS, BMJ Open Respiratory Research, MDPI, Thorax, Justia Dockets & Filings, News24, News24 Business, The New England Journal of Medicine, Independent Online, Personal Finance and
A Reconstructionist rabbi into mediation, mindfulness, music and creative explorations of spirituality, writing. lgbtq issues (& a closet jazz/cabaret singer!)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Steven

Contact Steven, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial

|
By Steven Nathan
| consultantlive.com
Phase 3 results from the TETON-1 trial, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, demonstrated that nebulized treprostinil (Tyvaso; United Therapeutics) significantly slowed lung function decline and reduced clinical worsening events in patients with idiopathic pulmonary fibrosis (IPF) over 52 weeks.1,2 The findings, alongside combined analyses of TETON-1 and the previously completed TETON-2 trial, represent what investigators are calling an...
Open in Who Shared View Duplicates (2) Issue with article?

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

|
By Steven Nathan
| nej.md
Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes This article was published on May 18, 2026, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by United Therapeutics. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

|
By Steven Nathan
| nej.md
Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes This article was published on May 18, 2026, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by United Therapeutics. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?
See all 135 licensed articles (198 Total)